# Kiniksa Pharmaceuticals International, plc

Summary updated: 2026-10-02T16:21:12.270872Z
Canonical: https://finbar.com/research/companies/kiniksa-pharmaceuticals-international-plc

## Overview

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company founded in 2015 that develops and commercializes therapies for unmet medical needs, with a focus on cardiovascular indications. Its stated purpose emphasizes putting patients first and developing novel, life-changing therapies. [1](https://app.finbar.com/go?id=P12611367)[2](https://www.kiniksa.com/about)

Its principal commercial product is ARCALYST (rilonacept), approved in the United States for recurrent pericarditis and certain autoinflammatory diseases; KPL-387 is an investigational therapy for recurrent pericarditis. [3](https://app.finbar.com/go?id=P35366790)[4](https://app.finbar.com/go?id=P25057125) Kiniksa reported $677.6 million in revenue for 2025, all of it U.S. product revenue. [5](https://app.finbar.com/go?id=T10966259)[6](https://app.finbar.com/go?id=T12390882)
[1](https://app.finbar.com/go?id=P12611367)[2](https://www.kiniksa.com/about)[3](https://app.finbar.com/go?id=P35366790)[4](https://app.finbar.com/go?id=P25057125)[5](https://app.finbar.com/go?id=T10966259)[6](https://app.finbar.com/go?id=T12390882)[2](https://www.kiniksa.com/about)

## Products & services

Kiniksa’s marketed product is ARCALYST (rilonacept), an IL-1α/IL-1β cytokine trap. It is FDA-approved in the U.S. for recurrent pericarditis in adults and patients aged 12 and older, cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in adults and patients aged 12 and older, and maintenance of remission in deficiency of the interleukin-1 receptor antagonist (DIRA) in adults and children weighing at least 10 kg. Kiniksa commercializes ARCALYST in the U.S. under a profit-sharing arrangement with Regeneron. [7](https://app.finbar.com/go?id=P143977164)[3](https://app.finbar.com/go?id=P35366790)

KPL-387 is an investigational, fully human IgG2 monoclonal antibody that binds IL-1R1 and inhibits IL-1α/IL-1β signaling. It is being developed for recurrent pericarditis; its Phase 3 PASTORALE trial began enrollment and dosing in July 2026, following Phase 2 evaluation that included monthly 300 mg subcutaneous dosing. [8](https://app.finbar.com/go?id=P143977165) KPL-1161 is a preclinical, Fc-modified IgG2 antibody that also binds IL-1R1. The Fc modification is intended to extend its half-life relative to KPL-387 and may support quarterly subcutaneous dosing. [9](https://app.finbar.com/go?id=P109053901)[10](https://app.finbar.com/go?id=P24945435)

Abiprubart is an investigational monoclonal antibody that inhibits the CD40–CD154 costimulatory interaction. It was studied in Phase 2 rheumatoid arthritis and Phase 2b Sjögren’s disease; Kiniksa announced it would discontinue development in Sjögren’s disease and explore strategic alternatives for the program. [11](https://app.finbar.com/go?id=P54573867)[12](https://app.finbar.com/go?id=P19273392)
[7](https://app.finbar.com/go?id=P143977164)[3](https://app.finbar.com/go?id=P35366790)[8](https://app.finbar.com/go?id=P143977165)[9](https://app.finbar.com/go?id=P109053901)[10](https://app.finbar.com/go?id=P24945435)[11](https://app.finbar.com/go?id=P54573867)[12](https://app.finbar.com/go?id=P19273392)

## Geographic presence

Kiniksa Pharmaceuticals International, plc lists its principal executive office in London, United Kingdom. Its filing also gives an address for Kiniksa Pharmaceuticals Corp. in Lexington, Massachusetts, separately identified for service of process rather than as the principal executive office. [13](https://app.finbar.com/go?id=P143976916)[14](https://app.finbar.com/go?id=P143976917)[15](https://app.finbar.com/go?id=P143976918)[16](https://app.finbar.com/go?id=P143976919)[17](https://app.finbar.com/go?id=P143976920)[18](https://app.finbar.com/go?id=P143976921)[19](https://app.finbar.com/go?id=P143976922)[20](https://app.finbar.com/go?id=P143976923)

ARCALYST is approved for sale only in the United States and is distributed there through a third-party logistics provider and specialty pharmacies. The company expects substantially all of its product revenue to come from the U.S. for the foreseeable future; its filings do not provide a geographic revenue breakdown or country-level revenue percentages. [21](https://app.finbar.com/go?id=P143977172)

Kiniksa has granted Huadong exclusive development and commercialization rights for ARCALYST across China, Hong Kong, Macao, Taiwan, India, New Zealand, and other named Asian markets. This is a partner territory, rather than evidence of direct Kiniksa sales in those countries. [22](https://app.finbar.com/go?id=P143977177)[23](https://app.finbar.com/go?id=P143977178) The company’s disclosed subsidiaries are located in the United States, United Kingdom, Switzerland, Germany, and France. [24](https://app.finbar.com/go?id=P95464279) Its filings do not disclose employee counts by location. Kiniksa relies on third parties for commercial manufacturing, and the cited disclosure does not specify their manufacturing-site locations. [25](https://app.finbar.com/go?id=P61891424)
[13](https://app.finbar.com/go?id=P143976916)[14](https://app.finbar.com/go?id=P143976917)[15](https://app.finbar.com/go?id=P143976918)[16](https://app.finbar.com/go?id=P143976919)[17](https://app.finbar.com/go?id=P143976920)[18](https://app.finbar.com/go?id=P143976921)[19](https://app.finbar.com/go?id=P143976922)[20](https://app.finbar.com/go?id=P143976923)[21](https://app.finbar.com/go?id=P143977172)[22](https://app.finbar.com/go?id=P143977177)[23](https://app.finbar.com/go?id=P143977178)[24](https://app.finbar.com/go?id=P95464279)[25](https://app.finbar.com/go?id=P61891424)

## Business segments

Kiniksa Pharmaceuticals reports one operating segment, managed on a consolidated basis. Its filings do not disclose separate segment revenue or percentage contributions by business area, product, or geography. [26](https://app.finbar.com/go?id=P143977146)[27](https://app.finbar.com/go?id=P26236717)

The commercial revenue mix is effectively 100% ARCALYST product revenue: in the first half of 2026, the company reported product revenue and no license or collaboration revenue. This is a product-revenue mix, not a separately reported segment breakdown. [7](https://app.finbar.com/go?id=P143977164)[28](https://app.finbar.com/go?id=T16475042)
[26](https://app.finbar.com/go?id=P143977146)[27](https://app.finbar.com/go?id=P26236717)[7](https://app.finbar.com/go?id=P143977164)[28](https://app.finbar.com/go?id=T16475042)[29](https://www.sec.gov/Archives/edgar/data/1730430/000110465926087545/knsa-20260630x10q.htm)

## Company history

Founded in 2015, Kiniksa began building its development portfolio through a series of asset acquisitions and licensing agreements. In September 2016, it acquired Biogen assets including KPL-716; in 2017, it licensed rilonacept from Regeneron, mavrilimumab from MedImmune, and research rights to KPL-404 from Primatope. Kiniksa later acquired Primatope in March 2019. [2](https://www.kiniksa.com/about) [30](https://app.finbar.com/go?id=P182545324) [31](https://app.finbar.com/go?id=P182545844) [32](https://app.finbar.com/go?id=P182546286)

Kiniksa completed its initial public offering in May 2018. In 2020, its Phase 3 RHAPSODY trial of rilonacept met its primary and major secondary endpoints. The FDA approved ARCALYST (rilonacept) for recurrent pericarditis in March 2021, and Kiniksa announced U.S. commercial availability the following month. [33](https://app.finbar.com/go?id=P182546601) [34](https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-positive-data-phase-3-trial-rilonacept/) [35](https://app.finbar.com/go?id=P103953777)

In 2022, Kiniksa granted Genentech exclusive worldwide rights to develop and commercialize vixarelimab and related antibodies. On June 27, 2024, a court-approved scheme redomiciled the parent company from Bermuda to the United Kingdom. [36](https://app.finbar.com/go?id=P44711015) [37](https://app.finbar.com/go?id=P37154476)

## Sources

1. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P12611367)
2. [www.kiniksa.com](https://www.kiniksa.com/about)
3. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P35366790)
4. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P25057125)
5. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=T10966259)
6. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=T12390882)
7. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143977164)
8. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143977165)
9. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P109053901)
10. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P24945435)
11. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P54573867)
12. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P19273392)
13. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976916)
14. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976917)
15. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976918)
16. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976919)
17. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976920)
18. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976921)
19. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976922)
20. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143976923)
21. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143977172)
22. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143977177)
23. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143977178)
24. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P95464279)
25. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P61891424)
26. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143977146)
27. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P26236717)
28. [Kiniksa Pharmaceuticals International, plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16475042)
29. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1730430/000110465926087545/knsa-20260630x10q.htm)
30. [Kiniksa Pharmaceuticals International, plc — Full financial report (2018 Y)](https://app.finbar.com/go?id=P182545324)
31. [Kiniksa Pharmaceuticals International, plc — Full financial report (2018 Y)](https://app.finbar.com/go?id=P182545844)
32. [Kiniksa Pharmaceuticals International, plc — Full financial report (2018 Y)](https://app.finbar.com/go?id=P182546286)
33. [Kiniksa Pharmaceuticals International, plc — Full financial report (2018 Y)](https://app.finbar.com/go?id=P182546601)
34. [investors.kiniksa.com](https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-positive-data-phase-3-trial-rilonacept/)
35. [Kiniksa Pharmaceuticals International, plc — Full financial report (2021 Y)](https://app.finbar.com/go?id=P103953777)
36. [Kiniksa Pharmaceuticals International, plc — Full financial report (2022 Y)](https://app.finbar.com/go?id=P44711015)
37. [Kiniksa Pharmaceuticals International, plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P37154476)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.